journal article·2020-09Open access

An Alternative Perspective towards Reducing the Risk of Engineered Nanomaterials to Human Health

Martin J. D. Clift, Gareth J. S. Jenkins, Shareen H. Doak

Small· Volume 16· Issue 36

Abstract

Abstract To elucidate the impact of human exposure to engineered nanomaterials, advanced in vitro models are a valid non‐animal alternative. Despite significant gains over the last decade, implementation of these approaches remains limited. This work discusses the current state‐of‐the‐art and how future developments can lead to advanced in vitro models better supporting nano‐hazard assessment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticles: synthesis and applications · Microplastics and Plastic Pollution · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

In Vitro Toxicology Group Institute of Life Sciences Swansea University Medical School Singleton Park Campus Swansea Wales SA2 8PP UK

Funding

Horizon 2020 Framework Programme

References (64)

Show source-provided references
1. European Union Definition of a Nanomaterial (2011/696/EU) https://eur‐lex.europa.eu/legal‐content/EN/TXT/?uri=CELEX:32011H0696(accessed: March2020).
2. 10.1038/475031a10.1038/475031a ↗
3. International Organization for Standardization ISO/TS 229:2005 https://www.iso.org/committee/381983.html(accessed: March2020).
4. 10.1016/j.matpr.2017.11.18710.1016/j.matpr.2017.11.187 ↗
5. 10.1051/matecconf/20171290201310.1051/matecconf/201712902013 ↗
6. 10.1111/jdv.1594310.1111/jdv.15943 ↗
7. Titanium Dioxide Manufacturers Association (TDMA) https://tdma.info/what‐you‐should‐know‐about‐eu‐titanium‐dioxide‐regulations/(accessed: March2020).
8. 10.1021/es103300g10.1021/es103300g ↗
9. Jafari S. · 2018
10. 10.1016/j.addr.2013.07.01410.1016/j.addr.2013.07.014 ↗
11. 10.1016/S1369-7021(04)00627-310.1016/S1369-7021(04)00627-3 ↗
12. 10.3762/bjnano.6.18110.3762/bjnano.6.181 ↗
13. 10.1002/wnan.151310.1002/wnan.1513 ↗
14. 10.1186/1743-8977-3-1110.1186/1743-8977-3-11 ↗
15. 10.1289/ehp.733910.1289/ehp.7339 ↗
16. K.Savolainen U.Backman D.Brouwer B.Fadeel T.Fernandes T.Kuhlbusch R.Landsiedel I.Lynch L.Pylkkanen Nanosafety in Europe 2015–2025: Towards Safe and Sustainable Nanomaterials and Nanotechnology Innovations www.ttl.fi/en/publications/electronic_publications/pages/default.aspx(accessed: March 2020).
17. 10.1165/ajrcmb/6.5.53510.1165/ajrcmb/6.5.535 ↗
18. 10.1136/oem.2004.01324310.1136/oem.2004.013243 ↗
19. 10.3109/1743539100377526610.3109/17435391003775266 ↗
20. 10.1289/EHP42410.1289/EHP424 ↗
21. 10.1186/s11671-018-2457-x10.1186/s11671-018-2457-x ↗
22. De Matteis V. · 2018
23. 10.1016/j.nantod.2016.06.00710.1016/j.nantod.2016.06.007 ↗
24. European Union Cosmetics Ban on Animal Experimentation (EC No 1223/2009) https://eur‐lex.europa.eu/legal‐content/EN/TXT/?uri=CELEX:02009R1223‐20190813(accessed: March2020).
25. 10.4103/0975-7406.9901610.4103/0975-7406.99016 ↗
26. 10.1093/toxsci/kfp14910.1093/toxsci/kfp149 ↗
27. 10.1016/j.yrtph.2017.10.02110.1016/j.yrtph.2017.10.021 ↗
28. 10.1517/14740338.7.2.10710.1517/14740338.7.2.107 ↗
29. 10.1016/0003-4878(95)00038-G10.1016/0003-4878(95)00038-G ↗
30. 10.1002/bdrc.2109610.1002/bdrc.21096 ↗
31. 10.1093/ilar/ilw02610.1093/ilar/ilw026 ↗
32. 10.1016/S0022-2275(20)34760-X10.1016/S0022-2275(20)34760-X ↗
33. 10.1097/00004032-198907001-0000510.1097/00004032-198907001-00005 ↗
34. 10.3109/08958378.2012.72578210.3109/08958378.2012.725782 ↗
35. 10.3390/ijerph1614257110.3390/ijerph16142571 ↗
36. 10.4049/jimmunol.172.5.273110.4049/jimmunol.172.5.2731 ↗
37. 10.1017/S1867299X0000515810.1017/S1867299X00005158 ↗
38. Cabrera‐Perez M. A. · 2016
39. 10.1093/mutage/gew05410.1093/mutage/gew054 ↗
40. 10.1515/ejnm-2014-001810.1515/ejnm-2014-0018 ↗
41. 10.1089/adt.2014.57310.1089/adt.2014.573 ↗
42. 10.1021/la500307q10.1021/la500307q ↗
43. 10.1007/s13530-019-0402-810.1007/s13530-019-0402-8 ↗
44. 10.1016/S0109-5641(96)80020-010.1016/S0109-5641(96)80020-0 ↗
45. 10.1016/S1369-7021(11)70058-X10.1016/S1369-7021(11)70058-X ↗
46. 10.1165/rcmb.2004-0187OC10.1165/rcmb.2004-0187OC ↗
47. 10.1152/ajprenal.00379.200610.1152/ajprenal.00379.2006 ↗
48. OECD Test No. 487: In Vitro Mammalian Cell Micronucleus Test https://www.oecd.org/env/ehs/testing/test‐no‐487‐in‐vitro‐mammalian‐cell‐micronucleus‐test‐9789264264861‐en.htm(accessed: March2020).
49. 10.1093/toxsci/kft21610.1093/toxsci/kft216 ↗
50. 10.1016/j.mimet.2020.10587910.1016/j.mimet.2020.105879 ↗
51. 10.1021/acsami.7b0347910.1021/acsami.7b03479 ↗
52. 10.1242/jcs.16778310.1242/jcs.167783 ↗
53. 10.1038/s41578-018-0034-710.1038/s41578-018-0034-7 ↗
54. 10.1089/aivt.2017.003410.1089/aivt.2017.0034 ↗
55. 10.1186/s12989-016-0161-510.1186/s12989-016-0161-5 ↗
56. 10.1039/C4LC01252F10.1039/C4LC01252F ↗
57. 10.1016/S0005-2736(00)00256-X10.1016/S0005-2736(00)00256-X ↗
58. 10.1007/978-94-011-6627-0_110.1007/978-94-011-6627-0_1 ↗
59. 10.14573/altex.2010.1.5310.14573/altex.2010.1.53 ↗
60. 10.1016/j.tox.2014.12.01210.1016/j.tox.2014.12.012 ↗
61. 10.3109/03639045.2013.83143910.3109/03639045.2013.831439 ↗
62. Adverse Outcome Pathway WIKI https://aopwiki.org/wiki/index.php/Aop:173(accessed: March2020).
63. 10.1186/s12989-016-0125-910.1186/s12989-016-0125-9 ↗
64. 10.1021/acsnano.9b0686010.1021/acsnano.9b06860 ↗